- Home
- XCUR vs ANTX Comparison
XCUR vs ANTX Comparison
Compare XCUR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.50
HOLD
Current Price
$1.11
Company Overview
Basic Information| Metric | XCUR | ANTX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 31.2M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | XCUR | ANTX |
|---|---|---|
| Price | $5.50 | $1.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 2.1M | 56.3K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $1.01 |
| 52 Week High | $17.50 | $1.55 |
Technical Indicators
Market Signals| Indicator | XCUR | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 42.77 |
| Support Level | $5.42 | $1.03 |
| Resistance Level | $6.56 | $1.15 |
| Average True Range (ATR) | 0.55 | 0.07 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 15.44 | 30.00 |
Price Performance
Historical Comparison XCUR
ANTX
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.